溶瘤腺病毒靶向治疗肿瘤干细胞的研究进展

Oncolytic Adenoviruses Targeted Treatment to Cancer Stem Cells

肿瘤干细胞(或肿瘤起始细胞)由于具有很强的肿瘤起始能力和浸润转移能力而成为许多肿瘤中难治性的细胞群体。有研究表明肿瘤干细胞对化疗、放疗抵抗,因此与肿瘤的复发有关。针对肿瘤干细胞治疗策略将会影响肿瘤治疗的成败,已有研究表明溶瘤腺病毒可通过感染的方式杀伤肿瘤干细胞,因此可以克服肿瘤干细胞对药物耐受、对放化疗抵抗的机制;另外,通过基因工程的方法在溶瘤腺病毒的构建过程中增加一些外源性抗肿瘤基因,还可促进溶瘤病毒的特异性和抗肿瘤活性。该文总结溶瘤腺病毒靶向针对肿瘤干细胞的研究进展,以期为今后的临床治疗和应用提供理论基础。

Cancer stem cells（CSCs） or cancer-initiating cells（CICs） embody the refractory nature observed among many cancers： very competent initial tumor establishment and extremely aggressive metastatic nature.Recent discoveries indicate that CSCs present chemo / radio-resistance and are thus thought to be responsible for the disease relapse.Hence,the success or failure of treatment may be influenced greatly by CSCs treatment strategy.Oncolytic viruses are proved by clinical trials to be able to kill cancer cells through mechanisms different from conventional therapeutics.And these viruses are not susceptible to the same pathways of drug or radiation resistance;furthermore,advanced generation of conditionally replicate adenoviruses（CRAds） can be armed with therapeutic transgenes to generate greater specificity and antitumor effects.Here is to make a review of the available data regarding the ability of oncolytic adenovirus to target CSCs for destruction,to provide a theoretical basis for future clinical practice.